^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Thyroid Gland Carcinoma |
| Drug: | belvarafenib (RG6185) (pan-RAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 2607: Antitumor activity of the selective RAF inhibitor HM95573 in solid tumors and hematologic malignancies
Excerpt:
HM95573 potently inhibited the growth of BRAFmutation CRC cell lines (e.g. IC50: 118nM for Colo-205) and thyroid cancer cell lines (43nM for B-CPAP); KRAS mutation NSCLC cell lines(297nM for Calu-6),CRC cell lines(65nM for HCT-116) and thyroid cancer cell lines(479nM for CAL-62)...
DOI:
10.1158/1538-7445.AM2015-2607
